相关临床试验
0
0 进行中
药物批准
90
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- The first 14 days after a specialty prescription is written represent a critical window where treatment initiation either succeeds or stalls due to access, affordability, and coordination barriers. - Up to 67% of patients abandon oral cancer therapies and over 50% abandon anti-inflammatory drugs, with abandonment rates approaching 60-70% when out-of-pocket costs exceed $250. - Walgreens Specialty Pharmacy's proactive model achieves 92% medication adherence compared to an 80% industry benchmark, with 56% of oncology patients paying $0 in copays. - Dedicated pharmacy operations program managers improved conversion by 43% and reduced turnaround time by two days versus network peers for a chronic inflammatory medication.
- UVA researchers analyzed 352 over-the-counter probiotic products from major U.S. pharmacy chains and found only 36 unique bacterial species, with no consistency in formulations linked to health claims. - The team developed HaPaPro, a collection of over 1,000 computer models of bacterial metabolism, to rationally design microbiome-targeted therapies. - Using HaPaPro, researchers successfully identified microbes with potential to prevent bacterial vaginosis, demonstrating the platform's therapeutic promise. - Findings published in Nature Microbiology highlight how computational modeling could lead to evidence-based probiotic products that deliver on their marketed health promises.
- A U.S. jury found Takeda Pharmaceutical liable for $885 million in damages for delaying generic competition of constipation drug Amitiza through an anticompetitive scheme. - The verdict marks the first time a pharmaceutical company has been found liable by a jury in class action litigation over pay-for-delay agreements since the 2013 Supreme Court ruling. - Under federal antitrust law, the $885 million award could be automatically tripled to several billion dollars, representing a significant financial penalty for the Japanese drugmaker. - The case centered on a 2014 settlement where Takeda allegedly paid Par Pharmaceutical $210 million to delay launching generic lubiprostone until January 2021, postponing competition by six years.
- K.C. Pharmaceuticals voluntarily recalled 3,111,072 bottles of over-the-counter eye drops in early March after the FDA cited a "lack of assurance of sterility." - The recalled products include multiple formulations sold under various brand names at major retailers including CVS, Walgreens, Rite Aid, Kroger, and other pharmacy chains. - The FDA classified this as a Class II recall, indicating the products may cause temporary or medically reversible adverse health consequences. - No injuries have been reported yet associated with the recalled eye drops, though consumers are advised to stop using affected products and contact retailers for refunds.
- ACON Laboratories launched the Flowflex Plus RSV + Flu A/B + COVID 4-in-1 test, marking the first FDA-cleared home diagnostic capable of detecting four major respiratory infections with a single nasal swab. - The test represents a breakthrough for pediatric care as the first respiratory home test cleared for use in children as young as six months, addressing critical RSV detection needs. - Early identification capabilities are particularly significant since RSV is the leading cause of hospitalization in young children according to the CDC. - The test is now available nationwide at major retailers including CVS, Walgreens, and Albertsons, supporting faster decision-making for families managing respiratory symptoms.
- Walmart will open clinical research sites this spring in three former Walmart Health locations and one rural store through partnership with Care Access research organization. - The initiative aims to address barriers to clinical trial participation by bringing research opportunities closer to underrepresented communities including rural residents and minorities. - Sites will offer health screenings and information about research studies, potentially providing participants early access to innovative treatments and therapies. - The expansion comes amid FDA efforts to improve diversity in clinical trials, as racial and ethnic minorities remain frequently underrepresented in biomedical research.
- TempraMed Technologies has launched VIVI Cap Smart, the world's first platform that combines temperature protection with digital tracking for insulin and GLP-1 pens. - The device integrates proprietary space-grade thermal insulation technology with digital health functionality, enabling automatic injection timing tracking and medication logging through a connected mobile application. - This launch represents TempraMed's strategic transition toward a comprehensive patient platform that combines physical device innovation with digital tools for chronic disease management. - The company has already achieved significant commercial traction with over 120,000 devices sold globally and distribution through major retailers and healthcare organizations including Maccabi Healthcare Services.
- The global cell and gene therapy market is expected to exceed $105 billion by 2033, driven by significant expansion in clinical pipelines with Phase I trials experiencing approximately 11% growth. - Cell therapy dominates the market with 61.2% share, reaching $14.66 billion in 2023, while manufacturing costs remain a challenge with CAR-T therapies exceeding $100,000 per patient. - North America leads the market with 43.7% share at $11.97 billion in 2023, supported by advanced regulatory frameworks including the FDA's RMAT designation for accelerated therapy review. - Advanced delivery vectors and viral vector platforms are driving innovation, with companies like AGC Biologics and Charles River Laboratories launching new manufacturing solutions to improve scalability and reduce costs.
- The FDA has approved updated COVID-19 vaccines for 2025-2026 but restricted their use to adults 65 and older and individuals with risk factors for severe COVID-19. - CVS Pharmacy cannot offer COVID-19 vaccines in 16 states including New York due to regulatory requirements and is awaiting CDC approval through ACIP recommendations. - Both CVS and Walgreens are limiting vaccine offerings to comply with state pharmacy laws and federal regulations, creating a patchwork of availability across the United States. - Access to the new vaccines depends on decisions by federal health advisers, health insurers, pharmacies, and state authorities, potentially delaying availability for weeks.
- Sycamore Partners has completed its acquisition of Walgreens Boots Alliance, taking the pharmacy giant private in partnership with Stefano Pessina and his family. - WBA shareholders received $11.45 per share in cash consideration, with potential for an additional $3.00 per share from future VillageMD monetization proceeds. - Following the transaction closure, Walgreens, Boots Group, Shields Health Solutions, CareCentrix and VillageMD will operate as separate standalone companies under private ownership. - The acquisition removes WBA from Nasdaq trading and marks a new chapter for the global pharmacy and healthcare services conglomerate.
